Owner BOEHRINGER INGELHEIM INTERNATIONAL GMBH BOEHRINGER INGELHEIM PHARMACEUTICALS INC.

Inventors Van Dongen, Augustinus Antonius Maria Silvester; Ostermann, Elinborg; Patzelt, Erik; Sproll, Marlies; Miglietta, John J.; Heider, Karl-Heinz; Adolf, Gunther

Agent Davies Collison Cave

Pub. Number AU-A-2002310823

PCT Number PCT/EP02/05467

PCT Pub. Number WO2002/094879

Priority 60/325,147 26.09.01 US; 01112237.1 18.05.01 EP

Filing date 17 May 2002

Wipo publication date 3 December 2002

C07K 016/28 Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C07K 016/46 Immunoglobulins, e.g. monoclonal or polyclonal antibodies - Hybrid immunoglobulins

C12N 015/13 Mutation or genetic engineering - Immunoglobulins

A61K 047/48 Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

A61P 035/04 Antineoplastic agents

A61P 035/00 Antineoplastic agents

A61K 047/10 Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Alcohols

A61K 031/00

A61K 051/10 Preparations containing radioactive substances for use in therapy or testing

C12N 015/62 Mutation or genetic engineering - DNA sequences coding for fusion proteins

C12N 005/10 Undifferentiated human, animal or plant cells, e.g. cell lines - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

C12N 015/63 Mutation or genetic engineering - Introduction of foreign genetic material using vectors